MARKET

HROW

HROW

Harrow Health Inc
NASDAQ
28.54
-0.83
-2.83%
Opening 15:16 11/12 EST
OPEN
29.54
PREV CLOSE
29.37
HIGH
29.54
LOW
28.40
VOLUME
356.24K
TURNOVER
--
52 WEEK HIGH
54.85
52 WEEK LOW
25.76
MARKET CAP
1.07B
P/E (TTM)
-36.9233
1D
5D
1M
3M
1Y
5Y
1D
Harrow Health: Strong Growth and Strategic Expansion Support Buy Rating; Price Target Unchanged at $63
TipRanks · 1d ago
Harrow Price Target Maintained With a $63.00/Share by BTIG
Dow Jones · 1d ago
BTIG Reiterates Buy on Harrow, Maintains $63 Price Target
Benzinga · 1d ago
Notable Tuesday Option Activity: HROW, CLOV, RCAT
NASDAQ · 2d ago
Harrow reports Q3 EPS 25c, consensus 30c
TipRanks · 2d ago
Harrow backs FY26 revenue view $350M-$365M, consensus $349.66M
TipRanks · 2d ago
Closing Bell Movers: Sanmina jumps over 20% on Q4 earnings beat
TipRanks · 2d ago
Harrow stock jumps as eye-care products deliver record Q3 sales
Seeking Alpha · 2d ago
More
About HROW
Harrow, Inc. is a provider of ophthalmic disease management solutions. It offers a portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in the United States, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, FLAREX, NATACYN, BYQLOVI and others. Its development-stage programs include MELT-300, H-N08, CR-01, and MELT-210. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms.

Webull offers Harrow Inc stock information, including NASDAQ: HROW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HROW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HROW stock methods without spending real money on the virtual paper trading platform.